07:00 , Sep 29, 2008 |  BC Week In Review  |  Company News

Asterion, Genzyme deal

Asterion granted Genzyme an option to license exclusive, worldwide rights to a long-acting version of an undisclosed, non-cytokine protein. Genzyme will have access to IP covering the protein and will conduct research on the development...
07:00 , May 28, 2007 |  BC Week In Review  |  Company News

Asterion management update

Asterion Ltd. , Sheffield, U.K.   Business: Endocrine, Autoimmune, Cancer   Hired: Raymond Barlow as CEO, formerly managing director at BD Solutions U.K.; he replaces Peter Grant, who will remain a non-executive director  ...
07:00 , May 28, 2007 |  BC Week In Review  |  Company News

Asterion board of directors update

Asterion Ltd. , Sheffield, U.K.   Business: Endocrine, Autoimmune, Cancer   Appointed: Kevin Bryett, former VP of policy, communications and corporate affairs at the Chiron Vaccines unit of Novartis AG 's Chiron Corp. subsidiary, as...
08:00 , Jan 16, 2006 |  BioCentury  |  Strategy

Independently minded Ipsen

Rather than put itself up for sale like other European specialty pharma plays, Ipsen Group is taking a different tack. Having raised E171 million ($203 million) in a December IPO, the company is planning to...
08:00 , Nov 10, 2003 |  BC Week In Review  |  Company News

Interleukin Genetics, Molecular Skin, University of Sheffield deal

ILGN received about 5% of the outstanding equity of Molecular SkinCare in exchange for granting to Molecular SkinCare and Asterion Ltd. (Sheffield, U.K.) rights to certain IP originally licensed to ILGN by the university. Molecular...